American and Canadian pharmacist associations warn that recent drug importation policies could put patients at risk
August 2026
The Canadian Pharmacists Association (CPhA) and the American Pharmacists Association (APhA) have issued a joint statement opposing U.S. policies that would facilitate the large-scale importation of prescription drugs from Canada.
The statement comes as the United States expands implementation of Section 804 importation programs, including recent FDA authorization of Colorado’s program.
While CPhA and APhA recognize the significant challenges many Americans face in accessing affordable prescription medicines, importing drugs from Canada is not a sustainable solution. The associations warn that large-scale importation could pose risks to patient safety and continuity of care, compromise supply-chain integrity and put additional pressure on Canada’s drug supply.
Canada’s pharmaceutical supply system is designed to meet the needs of its population. Increased demand from the much larger U.S. market could contribute to or exacerbate drug shortages and reduce timely access to medications for Canadian patients.
CPhA and APhA are calling for sustainable approaches to improving medication affordability that protect patient safety and strengthen drug supply resilience in both countries.